Navigation Links
ADHD Treatment -Phase 3 data on Lisdexamfetamine dimesylate Presented

The investigational ADHD treatment, lisdexamfetamine dimesylate (also known as NRP104 or LDX) by Shire plc and its collaborative partner// New River Pharmacuticals has yielded a good response in children with Attention Deficit Hyperactivity Disorder, it was announced today.

The data was presented at a national meeting of child and adolescent psychiatrists last weekend.

The study was done on 269 children between 6 and 12 who were treated for six months in an open label phase III study. A 60% improvement has been recorded in the primary ratings scale scores for ADHD symptoms, so the potential for LDX to be used effectively in ADHD has been recognised.

New River Pharmaceuticals formulated LDX as a new medication for ADHD which will act all day till 6 p.m.

Source-Eurekalert
MAL
'"/>




Page: 1

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress – ... to choose the best drug option for each patient. Dentists have several general anesthesia ... overall outcomes. , Researchers from the Tokyo Dental College in Tokyo, Japan wanted to ...
(Date:1/17/2017)... AZ (PRWEB) , ... January 17, 2017 , ... ... and improved supplement, Healthful-Flex. , The company, owned and operated by Ed ... public at a reasonable price with the highest level of customer service. Healthful ...
(Date:1/17/2017)... ... January 17, 2017 , ... Achieve TMS West, with ... a new office in San Clemente, California this month. Achieve TMS West is ... successfully treating individuals struggling with major depression. Depression impacts over 15 million adults ...
(Date:1/17/2017)... CA (PRWEB) , ... January 17, 2017 , ... A ... named winners of the fourth Cradle to Cradle Product Design Challenge , the ... fourth in a series of six circular design challenges scheduled to run through early ...
(Date:1/17/2017)... Gatos, CA (PRWEB) , ... January 17, 2017 , ... ... announced the results of a double blind clinical study for its dental gel that ... a leading national brand of toothpaste containing triclosan. The study was conducted at the ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan 17, 2017 Research and Markets ... by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product ... Global Forecast to 2021" report to their offering. ... The global active pharmaceutical ... from USD 157.95 Billion in 2016, growing at a CAGR of ...
(Date:1/17/2017)... WARSAW, Ind. , Jan. 17, 2017  Zimmer ... leader in musculoskeletal healthcare , today announced ... capitalizes on the strength of the Zimmer Biomet ... D. Delp will assume the position of ... of the Company. Mr. Delp previously served as Zimmer ...
(Date:1/17/2017)... , Jan. 17, 2017 Tempus, ... cancer care, and University Hospitals Seidman Cancer Center ... by making genomic data, advanced molecular analysis and ... researchers, physicians and healthcare providers. ... provide genomic and transcriptomic sequencing and analysis for ...
Breaking Medicine Technology: